GLP-1 Medications: How to Choose the Right One (2026)

Summary: Choosing between GLP-1 medications is a three-filter decision: the diagnosis on your chart decides which drugs have an approved indication, the trial evidence decides which one performs best for that goal, and coverage decides which one you can actually stay on.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

Choosing between GLP-1 medications is not a ranking exercise. It is a filter sequence, and the filters run in a fixed order: the diagnosis on your chart decides which drugs even have an approved indication for you, the trial evidence decides which of those performs best for the goal you care about, and access decides which one you can realistically stay on for years. Skip the first filter and you end up arguing about weight loss percentages for a drug your plan will never cover for you.

This page is the selection framework. For the drug-by-drug reference on every molecule in the class, including the older agents, see the full list of FDA-approved GLP-1 medications.

Filter 1: start with the diagnosis, not the drug

Every GLP-1 on the US market is approved for a specific list of conditions, and the indication is what unlocks both the prescription and the insurance decision. Two people with identical body weight get routed to different drugs because one has type 2 diabetes on file and the other does not.

If you want the whole injectable and oral field laid out side by side before narrowing it down, this catalog of GLP-1 medications collects the products in one view. Then come back to the filters, because breadth is not the decision, fit is.

One caveat worth stating plainly: an off-label prescription is legal and common, but it changes the coverage conversation completely. Semaglutide prescribed as Ozempic for weight loss in a patient without diabetes is off-label, will usually be denied by the plan, and pushes the cost into cash-pay territory.

Filter 2: what the trials actually measured

Trial numbers only mean something when the endpoint matches your goal. A drug can be first on weight and second on cardiovascular outcomes at the same time, which is exactly the situation in 2026.

Three things fall out of that table.

Tirzepatide leads on weight in the only direct comparison that has been run at maximum tolerated doses ^[3]. Semaglutide owns the hard outcomes evidence: cardiovascular events in people without diabetes and kidney events in people with diabetes and CKD ^[4][5]. Liraglutide sits well behind both on weight, and STEP 8 quantified that gap in a head-to-head design ^[8], which is why it now tends to be chosen for reasons other than efficacy, such as pediatric eligibility or a daily schedule that suits a specific patient.

Filter 3: access is the filter that actually decides

The drug you can pay for every month for three years beats the drug that scores higher in a trial you read once. Cost here is a structure, not a number, and the structure has four tiers that move in the same order regardless of what any given month's prices are.

1. Covered brand with a savings card. The cheapest route by a wide margin when the plan covers the indication. Savings cards usually carry annual caps and exclude government insurance.
2. Covered brand without a card. Standard formulary copay or coinsurance. Coinsurance on a high-cost drug can still be painful.
3. Manufacturer self-pay programs. Single-dose vial programs from the manufacturers sit below pharmacy retail for cash payers and supply the FDA-approved product.
4. Pharmacy retail cash price. The highest tier and the one advertised prices are measured against.

What moves you between tiers is not negotiation, it is documentation. Coverage odds improve when the chart carries a qualifying diagnosis, a documented BMI with a weight-related comorbidity, prior lifestyle intervention notes, and, for many plans, a failed or contraindicated alternative. Our pages on what GLP-1 treatment costs and how to qualify for a GLP-1 prescription cover the paperwork side in detail.

The six-question decision sequence

Run these in order. The first question that produces a clear answer usually ends the decision.

1. What is the qualifying diagnosis on my chart? Type 2 diabetes, obesity by BMI, overweight plus a comorbidity, established cardiovascular disease, CKD, sleep apnea. This is the filter that decides which products are even on the table.
2. What is the primary goal? Maximum weight reduction, A1C control, cardiovascular event reduction, kidney protection, or sleep apnea severity. Pick one primary. Secondary goals break ties later.
3. What does my plan cover for that diagnosis? Call the plan or check the formulary before the appointment. This answer changes the shortlist more often than the trial data does.
4. Can I tolerate the titration? Every drug in the class escalates slowly to manage nausea, vomiting, and constipation. If a previous attempt failed on GI side effects, the plan needs a slower ramp or a different agent, not a bigger starting dose.
5. Does the schedule fit my life? Weekly injection, daily injection, daily oral tablet. Adherence to a daily drug is measurably harder for most people than a weekly one.
6. What happens at month 12 and beyond? These are chronic therapies. Ask what the drug costs after any savings card cap resets, what the plan does at renewal, and what the stopping plan is if coverage ends.

Switching between GLP-1 medications

Switching is routine, and it is usually driven by coverage changes, supply, side effects, or a plateau rather than by a new trial result. A few rules apply across the class.

Dose does not transfer one for one. There is no validated conversion between semaglutide and tirzepatide milligrams, so a switch means restarting a titration, usually at or near the starting dose of the new drug, with the ramp shortened only if the prior drug was tolerated at a high dose. Your prescriber makes that call based on what you were actually taking.

Timing follows the half-life. Weekly agents are typically started one week after the last dose of the previous weekly agent. Moving from a daily agent such as liraglutide to a weekly one is simpler because the daily drug clears faster.

Expect the side effect clock to reset. GI symptoms cluster around dose escalation, so a switch usually brings back a few weeks of the same adjustment period you had at the start, even if you were symptom free before. The GLP-1 dosing chart lays out the standard titration schedules for each product.

A plateau is not automatically a reason to switch. Weight loss slows as body mass falls, and the trials show most of the curve flattening in the second year. Before switching, the useful checks are whether you reached the maintenance dose, whether protein intake and resistance training are in place, and whether doses have been missed.

Safety filters that override the ranking

Some findings take drugs off the table regardless of efficacy or coverage.

Discuss all of these with the prescribing clinician rather than screening yourself. Nothing here is a substitute for that conversation, and the drug choice is theirs to make with you. Our reference on GLP-1 side effects covers what to expect once therapy starts.

Common questions about choosing a GLP-1

Which GLP-1 medication produces the most weight loss?

Tirzepatide. In SURMOUNT-5, the head-to-head trial at maximum tolerated doses, tirzepatide produced a mean weight reduction of 20.2 percent versus 13.7 percent for semaglutide at 72 weeks.

If tirzepatide wins on weight, why would anyone choose semaglutide?

Because the endpoint may not be weight. Semaglutide has the cardiovascular outcomes evidence in adults without diabetes from SELECT and the kidney outcomes evidence from FLOW. It is also frequently the better-covered option depending on the plan and diagnosis.

Does the starting dose differ between GLP-1 medications?

Yes, and each product has its own titration schedule set by its label. What is consistent across the class is that therapy starts low and escalates over weeks to manage gastrointestinal side effects, not to test tolerance quickly.

Can I switch from one GLP-1 to another without restarting the titration?

Usually not entirely. There is no validated milligram-for-milligram conversion between molecules, so a switch means a new titration, sometimes shortened if the previous drug was tolerated at a high dose. That decision belongs to the prescriber.

Is a daily GLP-1 worse than a weekly one?

Not pharmacologically, but adherence to daily injections is harder for most people, and the daily agent with a weight management indication, liraglutide, produced markedly less weight loss than semaglutide in the STEP 8 head-to-head trial.

What if my insurance covers only one GLP-1?

Then that is usually the practical answer, provided it has an approved indication for your diagnosis and no contraindication applies. A drug you can stay on continuously outperforms a theoretically stronger drug you stop after two months.

Do I have to stay on a GLP-1 forever?

Obesity and type 2 diabetes are chronic conditions, and appetite and weight typically move back after stopping. Current practice treats these as long-term therapies, and any stopping plan should be made with the prescriber rather than by discontinuing abruptly.

Are compounded versions equivalent to the brand product?

No. Compounded preparations are not FDA-approved finished products and are made under different rules than the approved drugs. They are a separate decision with a separate risk assessment, not a discount version of the same medication.

Which GLP-1 is best if I have type 2 diabetes and heart disease?

Semaglutide is the most common answer because of the cardiovascular outcomes data, though tirzepatide produces larger A1C and weight reductions. The trade-off between outcomes evidence and glycemic potency is exactly the conversation to have with your clinician.

How long before I know a GLP-1 is working?

Appetite changes are often noticeable within the first few weeks, but the maintenance dose is what drives the trial-level results, and reaching it takes roughly four to five months on the standard schedules. Judging efficacy before then judges the titration, not the drug.

Bottom line

Run the filters in order. The diagnosis decides which GLP-1 medications are available to you, the evidence decides which one fits the goal, and coverage decides which one you can sustain. Tirzepatide is the strongest weight loss option in head-to-head data, semaglutide holds the cardiovascular and kidney outcomes evidence, and liraglutide remains relevant mostly for pediatric eligibility and daily-dose preference. The choice that fails is the one nobody can pay for in month seven.